Welcome to our dedicated page for Iqvia Hldgs SEC filings (Ticker: IQV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IQVIA Holdings Inc. (NYSE: IQV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. IQVIA’s filings confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol IQV.
IQVIA uses Form 8-K to report material events such as quarterly financial results, amendments to its credit agreements and leadership or board changes. For example, the company has filed 8-K reports describing financial results for specific quarters, an amendment to its Fifth Amended and Restated Credit Agreement and the planned transition of its chief financial officer. Other 8-K filings cover the appointment of new directors and related governance matters.
For investors analyzing IQVIA, these filings help explain the company’s financial condition, capital structure and key corporate developments. They also provide context for IQVIA’s role as a global provider of clinical research services, commercial insights and healthcare intelligence, including how it finances its operations and manages governance and leadership transitions.
On Stock Titan, SEC filings for IQVIA are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries help interpret lengthy filings by highlighting important sections, such as descriptions of material agreements, financial updates or changes in executive roles. Users can review 8-Ks for event-driven information and refer to other filing types, such as annual and quarterly reports when available, to gain a more complete view of IQVIA’s business and risks.
A planned Rule 144 sale has been filed for IQV common stock. The notice covers 36564 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of 8132875.67, while 170300000 shares are outstanding. The approximate sale date listed is 12/18/2025 on the NYSE.
The filing also discloses that Ari Bousbib sold 56557 common shares of the same issuer on 10/29/2025, generating gross proceeds of 12460983.24. These details show both the upcoming planned transaction and recent sales over the prior three months, as required under Rule 144 disclosure rules.
IQVIA Holdings Inc. reported that it entered into an amendment to its Fifth Amended and Restated Credit Agreement. The amendment refinances existing Term A-1 and Term A-2 dollar term loans into a new class of term A dollar loans, and refinances existing term A euro loans into a new class of term A euro loans. It also consolidates all current U.S., Japanese, and Swiss/Multicurrency revolving credit commitments into a new class of revolving credit commitments.
The amendment reduces the interest rate on term A loans and revolving credit loans denominated in U.S. dollars by eliminating the term SOFR credit spread adjustment. In addition, the Swiss Subsidiary Borrower and the Japanese Borrower are released from all obligations as borrowers under the credit agreement.
IQVIA Holdings Inc. (IQV): A newly appointed director, William G. Kaelin, Jr., filed a Form 3 initial statement of beneficial ownership. The filing indicates no securities are beneficially owned as of the event date 11/05/2025. The relationship is listed as Director, and the form was filed by one reporting person. The submission was signed by an attorney-in-fact.
IQVIA (IQV) director Leslie Wims Morris reported acquiring 146 deferred share units on 11/05/2025, coded as an award (A), at a disclosed derivative price of $210.12. Following the transaction, she beneficially owns 4,735 deferred share units, held directly.
Each deferred share converts into one share of common stock upon settlement. Per the plan, settlement occurs when the director service ends, upon a change in control, or upon death; there is no expiration date.
IQVIA Holdings (IQV): Form 4 shows director equity activity. Director Colleen A. Goggins acquired 181 deferred share units on 11/05/2025 at $210.12 each. Following the transaction, she holds 4,702 deferred share units directly.
Each deferred share converts 1-for-1 into IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, settlement occurs when the director ceases service, upon a change in control, or upon death. The deferred shares have no expiration date.
IQVIA Holdings Inc. (IQV) reported an insider equity change as a director acquired 193 deferred shares on 11/05/2025 at a recorded derivative security price of $210.12, according to a Form 4 filing.
Each deferred share is convertible into one share of common stock upon settlement, which occurs when the director ceases to serve, upon a change in control of the company, or upon death, with no expiry date. Following this transaction, the director beneficially owned 4,063 deferred share units directly.
IQVIA Holdings (IQV): Director Form 4 update. Director John G. Danhakl reported acquiring 158 deferred shares on 11/05/2025 at a price of $210.12 per unit. Following this transaction, he beneficially owned 2,772 derivative securities.
These deferred shares convert into one share of IQVIA common stock upon settlement. Under the company’s Non-Employee Director Deferral Plan, settlement occurs when the director leaves the board, upon a change in control of the company, or upon the director’s death. The deferred shares have no expiration date. Ownership is reported as direct.
IQVIA Holdings Inc. appointed William G. Kaelin Jr., M.D. to its Board of Directors on November 5, 2025. The Board determined that Dr. Kaelin meets the New York Stock Exchange definition of an independent director. In connection with the appointment, he is expected to enter into the company’s standard indemnification agreement for non-management directors and will participate in the non-employee director compensation program described under “Director Compensation” in the proxy statement dated February 28, 2025. The company announced the appointment via a press release attached as Exhibit 99.1.
IQVIA Holdings Inc. (IQV): Executive Vice President and General Counsel Eric Sherbet reported insider transactions on 10/29/2025. He exercised stock appreciation rights at $131.82 to acquire 10,000 shares, then sold 4,000 shares at a weighted average price of $219.70 (ranging from $219.66 to $219.92) and 6,000 shares at $219.72. Following these trades, he directly owns 21,108 shares. The SARs related to 10,000 underlying shares (exercisable since 02/13/2022, expiring 02/13/2029), with 8,436 derivative securities remaining beneficially owned.
IQVIA (IQV) insider transaction: On 10/29/2025, Chairman, Chief Executive Officer & President Ari Bousbib exercised stock appreciation rights for 77,592 shares at an exercise price of $59.90, then sold shares in multiple open‑market transactions. The reported weighted average sale prices ranged from $216.70 to $222.27 across the disclosed trade batches.
Following these transactions, Bousbib beneficially owned 807,163 shares directly. He also reported 543,302 shares held indirectly by a trust.
FAQ
What is the current stock price of Iqvia Hldgs (IQV)?
What is the market cap of Iqvia Hldgs (IQV)?
